Nuo Therapeutics Selected to Exhibit Aurix® System at Vizient Innovative Technology Exchange
26 juin 2023 15h00 HE
|
Nuo Therapeutics, Inc.
HOUSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on...
Nuo Therapeutics’ Aurix® System Added To Wound Care Formulary Of Wound Care Advantage
22 juin 2023 08h30 HE
|
Nuo Therapeutics, Inc.
HOUSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on...
Nuo Therapeutics Provides Corporate and Business Update
30 août 2022 08h30 HE
|
Nuo Therapeutics, Inc.
Broad equity incentive agreement established with Pacific Medical, Inc. including initial equity purchase Favorable initial progress on establishing substantive distribution network in support of...
Nuo Therapeutics Responds to Mini-Tender Offer
04 févr. 2022 17h53 HE
|
Nuo Therapeutics, Inc.
HOUSTON, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (“Nuo” or the “Company”) announced that it is aware of an unsolicited “mini-tender” offer by Alternative Liquidity Index, LP to...
Nuo Therapeutics Receives Advisory Opinion Waiver for Medicare Part B Co-Payments for Patients in Aurix CED Clinical Studies
05 juil. 2017 08h00 HE
|
Nuo Therapeutics, Inc.
GAITHERSBURG, Md., July 05, 2017 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQX:AURX) (“Nuo” or the “Company”) announced today that the Office of Inspector General (OIG) of Department of Health...
Nuo Therapeutics Restructures Series A Preferred Stock with Deerfield
12 juin 2017 16h00 HE
|
Nuo Therapeutics, Inc.
GAITHERSBURG, Md., June 12, 2017 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQX:AURX) (the “Company”) announced today that it entered into an Exchange Agreement with entities affiliated with...
Nuo Therapeutics Obtains Stockholder Consent to Reverse Split
08 mai 2017 16h49 HE
|
Nuo Therapeutics, Inc.
GAITHERSBURG, Md., May 08, 2017 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQX:AURX) (the “Company”) announces receipt of the written consent of more than a majority of the voting power of its...
Nuo Therapeutics Appoints Dr. Paul D. Mintz to its Board of Directors
10 avr. 2017 06h00 HE
|
Nuo Therapeutics, Inc.
GAITHERSBURG, Md., April 10, 2017 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQX:AURX) (“Nuo” or the “Company”) announces the appointment of Paul D. Mintz, MD, Senior Vice President and Chief...
Nuo Therapeutics Provides Update on Public Market Trading Status
06 mars 2017 14h41 HE
|
Nuo Therapeutics, Inc.
GAITHERSBURG, Md., March 06, 2017 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB:AURX) (“Nuo” or the “Company”), announced today that the Depository Trust Company (“DTC”) has approved the...
Nuo Therapeutics Announces Execution of Third Limited Consent With Deerfield Management Through January 7, 2016
18 déc. 2015 17h15 HE
|
Nuo Therapeutics, Inc.
GAITHERSBURG, Md., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQX:NUOT), today announced that the Company has entered into a third limited consent with Deerfield Management, L.P....